Switzerland's Berna Biotech Ltd. is acquiring Rhein Biotech NV, of the Netherlands, in a combined cash and shares deal valued at EUR279 million (US$257 million). The transaction would create a pan-European vaccines powerhouse that aims to achieve revenues of EUR300 million by 2005. (BioWorld International)